Gene Therapies Move From Experimental to Available for Rare Diseases

Gene therapies, long the stuff of scientific promise, are increasingly moving from the experimental realm into approved treatments, transforming care for a growing list of rare diseases that once had few or no options.

These therapies work by addressing the genetic root of a disease rather than merely managing symptoms, and for some conditions they offer the prospect of durable, even one-time, treatment. For patients and families, the arrival of an option can be life-changing.

Real progress

The list of approved therapies has expanded steadily, spanning certain inherited disorders, some blood conditions, and select vision-related diseases. Each approval represents years of research finally reaching the people it was meant to help.

The advances are not without complexity. The treatments are highly specialized, delivered at a limited number of centers, and their long-term durability is still being studied as the first cohorts of patients are followed over time.

Access and cost

The central challenges now are access and cost. Many gene therapies carry extraordinary price tags, raising hard questions about how health systems pay for one-time treatments with lasting benefits. Resolving those questions, experts say, will determine whether the scientific breakthroughs reach everyone who could benefit.